aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
KalVista Pharmaceuticals, founded with a mission to address significant unmet medical needs, focuses on the discovery, development, and commercialization of small molecule protease inhibitors. The company's primary market is the United States and the United Kingdom, where it aims to transform the treatment landscape for hereditary angioedema (HAE) through innovative, orally-delivered medicines. KalVista is committed to empowering individuals to live beyond the challenges of their diseases.
Notable affiliated individuals include experienced scientists and industry leaders who drive the company's research and development efforts. KalVista has secured investments from prominent venture capital firms, bolstering its financial stability and growth potential. Key achievements include advancing several promising candidates in clinical trials, positioning the company as a leader in HAE treatment innovation. The overall impact of KalVista Pharmaceuticals lies in its potential to significantly improve the quality of life for patients with HAE through groundbreaking therapeutic options.
Operating Status
Acquired
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was KalVista Pharmaceuticals founded?
KalVista Pharmaceuticals was founded in 2004.
Where is KalVista Pharmaceuticals's headquarters located?
KalVista Pharmaceuticals's headquarters is located in Cambridge, MA, US.
When was KalVista Pharmaceuticals's last funding round?
KalVista Pharmaceuticals's most recent funding round was for $58M (USD) in December 2022.
How many employees does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 118 employees as of Feb 6, 2024.
How much has KalVista Pharmaceuticals raised to-date?
As of July 05, 2023, KalVista Pharmaceuticals has raised a total of $292.5M (USD) since Dec 27, 2022.
Add Comparison
Total Raised to Date
$292.5M
USD
Last Update Dec 27, 2022
Last Deal Details
$58M
USD
Dec 27, 2022
Post Ipo Equity
Total Employees Over Time
118
As of Feb 2024
KalVista Pharmaceuticals Address
55 Cambridge Parkway
suite 901e
Cambridge,
Massachusetts
02142
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts